ClinConnect ClinConnect Logo
Search / Trial NCT04822064

Comparison of Oral Chloral Hydrate and Combination of Intranasal Dexmedetomidine and Ketamine for Rescue After Failed Pediatric Procedural Sedation

Launched by SEOUL NATIONAL UNIVERSITY HOSPITAL · Mar 25, 2021

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

Pediatric Procedural Sedation Chloral Hydrate Intranasal Dexmedetomidine Intranasal Ketamine

ClinConnect Summary

This clinical trial is looking at two different methods to help children who need sedation for medical procedures when the first method doesn't work. In Korea, a common way to sedate young children is by giving them a medicine called oral chloral hydrate. However, if this doesn't work well, the study is testing whether a combination of two other medications—intranasal dexmedetomidine and ketamine—can be more effective in helping the child relax and be comfortable during the procedure. The researchers believe that this combination will help children settle down more quickly, within about 15 minutes.

To participate in this trial, children must be under 7 years old and need sedation for a procedure but have not responded well to oral chloral hydrate. There are some criteria that could exclude a child from joining, such as severe health issues or allergies to the medications being tested. If a child is eligible, they will be randomly assigned to receive either the standard oral chloral hydrate or the new combination of intranasal dexmedetomidine and ketamine. Parents can expect to be informed about the process and any potential risks, and the study aims to improve sedation options for young patients.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Pediatric patients who need procedural sedation (Age \< 7 years)
  • ASA (American Society of Anesthesiologists) physical status 1-3
  • Failed to induce sedation with oral chloral hydrate 50mg/kg
  • Exclusion Criteria:
  • ASA (American Society of Anesthesiologists) physical status 4-5
  • History of hypersensitivity to Dexmedetomidine, Ketamine, or Chloral hydrate
  • Recent administration of Alpha 2 adrenergic receptor agonist or antagonist
  • Cannot administrate oral medication (e.g. Swallowing difficulty)
  • Cannot administrate intranasal medication(e.g. Excessive rhinorrhea)
  • Unstable vital signs, Unstable arrhythmia

About Seoul National University Hospital

Seoul National University Hospital (SNUH) is a leading medical institution in South Korea, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent clinical trial sponsor, SNUH integrates cutting-edge scientific inquiry with patient-centered care, facilitating the development of novel therapies and treatment protocols. The hospital boasts a diverse range of specialized departments and a robust infrastructure for conducting clinical studies, ensuring rigorous adherence to ethical standards and regulatory compliance. By fostering collaboration among multidisciplinary teams, SNUH aims to contribute significantly to global medical advancements and improve patient outcomes.

Locations

Seoul, , Korea, Republic Of

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials